Breast Cancer: Tracey's Patient Story

Patient Info: Tracey

After surgery, Tracey planned continued monitoring with mammograms every 6 months.

Our Cancer StoriesRead more →

Breast Cancer: Mery's Patient Story

Patient Info: Mery

Mery said she was in remission after completing her main treatment and remained on hormone therapy.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Mia's Patient Story

Patient Info: Mia | Stage II

Mia completed treatment and continued to manage its physical, emotional, and financial effects.

Our Cancer StoriesRead more →

Stage IV Breast Cancer: Nathalie's Patient Story

Patient Info: Nathalie | Stage IV

Nathalie had been living with stage 4 breast cancer for more than three years and remained focused on time with her children.

Our Cancer StoriesRead more →

Breast Cancer: Doranci's Survivor Story

Patient Info: Doranci

Doranci said her breast cancer was in remission after mastectomy, lymph-node surgery, chemotherapy, radiation therapy, and hormone therapy.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Lily's Patient Story

Patient Info: Lily | Stage II

Lily had undergone lumpectomy, lymph-node surgery, chemotherapy, and radiation for stage 2 breast cancer and focused on staying positive after treatment.

Our Cancer StoriesRead more →

Stage I Breast Cancer: Kelly's Survivor Story

Patient Info: Kelly, Female, 70+ | Stage I

Kelly completed treatment for Stage I breast cancer and remained in remission while continuing medication to help keep the cancer from returning.

Our Cancer StoriesRead more →

Locally advanced lung adenocarcinoma: neoadjuvant treatment, surgery, and fistula repair

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Three months after reconstruction for postoperative esophagopleural fistula, her nutritional status had improved and esophagogram showed no anastomotic leak; long-term lung cancer control was not reported.

PubMed CentralRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: response to triple targeted therapy and surgery

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR exon 19 deletion; acquired BRAF V600E mutation in progressive lesion while EGFR exon 19 deletion persisted

Metastatic Site: pleura, pulmonary metastases; mediastinal and left…

As of May 2025, she continued osimertinib, dabrafenib, and trametinib after segmentectomy/lymphadenectomy, with 1% viable residual tumor in resected lung lesions, complete nodal pathologic response, and no disease progression.

PubMed CentralRead more →

Stage IIIB ER/PR-positive breast cancer: emergency mastectomy for infected fungating tumor

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER >75%; PR >75%; HER2 0 / HER2-negative; grade 3 invasive ductal carcinoma

As of May 2025, management centered on anastrozole after emergency mastectomy, repeated debridements, wound care, and major postoperative complications; oncology follow-up had become inconsistent because of ongoing medical setbacks.

PubMed CentralRead more →

Stage IIIA double ALK-fusion lung adenocarcinoma: major pathological response to neoadjuvant alectinib

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: ALK-rearranged lung adenocarcinoma with both ELMOD3-ALK and EML4-ALK fusions. CEA/NSE/CA19-9 decreased after alectinib.

As of April 2025, he had continued alectinib for 4 years after surgery, with more than 48 months of disease-free survival, no recurrence, and no serious drug-related toxicity.

PubMed CentralRead more →

HER2 exon 20 metastatic lung adenocarcinoma with pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 exon 20 insertion lung adenocarcinoma with TP53 mutation, PD-L1 TPS 50%, and low TMB.

Metastatic Site: contralateral lung

Right lower lobectomy with radical lymphadenectomy in November 2023 showed pathologic complete response, and no additional therapy was offered after surgery.

PubMed CentralRead more →

Localized low-grade bronchial chondrosarcoma: surgery with no recurrence at 12 months

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported. Histology showed a low-grade cartilage-type tumor.

As of December 2025, follow-up bronchoscopy, CT, and clinical evaluation through 12 months after surgery showed good healing and no recurrence.

PubMed CentralRead more →

Gastric cancer recurring in the rectum about 20 months after gastrectomy

Patient Info: Anonymized, Male, 60s | Stage IV

Metastatic Site: rectum, peritoneum

Metastatic gastric adenocarcinoma involved the rectum and pericolonic fat, with peritoneal nodules seen at surgery. He died 6 months after the rectal operation.

PubMed CentralRead more →

Stage 4 lung LCNEC: major response to chemotherapy plus immunotherapy

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: Large-cell neuroendocrine lung cancer markers were positive. PD-L1 was negative

Metastatic Site: left adrenal gland

By July 2024, PET-CT showed complete metabolic response of the adrenal metastasis, no visible adrenal disease, no pulmonary recurrence, and no distant metastasis after immunochemotherapy, lobectomy, adjuvant therapy, and serplulimab maintenance.

PubMed CentralRead more →

Stage IIIA EGFR-mutated lung adenocarcinoma: surgery after osimertinib

Patient Info: Anonymized, Male, 60s

Biomarkers: EGFR E746_A750 deletion; PD-L1 TPS 15%; TMB 5.01 Muts/Mb; TTF-1 3+; CK7 3+; Ki67 60%

As of July 2024, surveillance CT scans at 2, 6, and 12 months after surgery showed no recurrent malignancy while he continued adjuvant osimertinib.

PubMed CentralRead more →

Stage 3 EGFR-mutant lung cancer: osimertinib response to surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion; PD-L1 tumor proportion score <=1%

No recurrence or metastasis was reported after neoadjuvant osimertinib, R0 left upper lobectomy with mediastinal lymphadenectomy, and ongoing adjuvant osimertinib for Stage IIIA EGFR exon 19 deletion lung adenocarcinoma.

PubMed CentralRead more →

Secretory breast cancer: mastectomy and radiotherapy to no evidence of disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 50%; tumor-infiltrating lymphocytes 60%

As of May 2024, 6 months after mastectomy and adjuvant radiotherapy for pT2N0M0 triple-negative secretory breast cancer, clinical examination and imaging showed no evidence of relapse.

PubMed CentralRead more →

Lung cancer with limited spread, treated with a combination of therapies

Patient Info: Anonymized, Female

She remained free of recurrence for 164 months, with excellent quality of life and no neurological after-effects.

PubMed CentralRead more →

Stage II Breast Cancer: Daniela's Survivor Story

Patient Info: Daniela, Female, 50s | Stage II

Daniela was declared cancer-free in March 2024 after mastectomy, lymphadenectomy, chemotherapy, and radiation therapy for Stage II breast cancer.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Margaret's Patient Story

Patient Info: Margaret | Stage III

Margaret remained hopeful while managing severe treatment effects, sepsis, financial pressure, and reduced time with her children.

Our Cancer StoriesRead more →

Stage I Breast Cancer: Hu's Patient Story

Patient Info: Hu Jia, Female | Stage I

As of 2023, Hu Jia was in treatment for Stage I breast cancer after choosing a modified plan that excluded lymphadenectomy, while anticipating future medication costs and focusing on diet, art, reflection, and emotional resilience.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Joanna's Survivor Story

Patient Info: Joanna, Female, Under 40 | Stage III

By late 2023, Joanna had completed treatment for Stage III breast cancer, was no longer taking medication, and described herself as living free of cancer.

Our Cancer StoriesRead more →

Breast Cancer: Mina's Patient Story

Patient Info: Mina

Mina completed surgery and radiation treatment and remained on hormone therapy.

Our Cancer StoriesRead more →